CaitlinElizabethTaylorMD

PubMed

• 2 citations
  Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.
  Caitlin Taylor, Jane Meisel, Aimee J Foreman, Christy Russell, Dipankar Bandyopadhyay, Xiaoyan Deng, Lisa Floyd, Amelia Zelnak, Harry Bear, Ruth O'Regan> ;Breast Cancer Research and Treatment. 2023 May 1
• Passenger pathogens on physicians.
  Christopher Ronald Funk, Sruthi Ravindranathan, Alex Matelski, Caitlin Taylor, Sanjay Chandrasekaran, Martha Arellano, Amelia A Langston, Nisha Joseph, Edmund K Waller...> ;American Journal of Infection Control. 2023 Jul 1
• 2 citations
  Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?
  Caitlin Taylor, Jane Meisel, Kevin Kalinsky> ;Therapeutic Advances in Medical Oncology. 2022 Jan 1
• 8 citations
  Management of Breast Cancer Therapy-Related Sexual Dysfunction.
  Caitlin E. Taylor, Jane L. Meisel> ;Oncology. 2017 Oct 15
• 3 citations
  Multidisciplinary Approaches to Chest Wall Recurrences of Breast Cancer.
  Cletus Arciero, Peter Thompson, Jane L. Meisel, Caitlin E. Taylor, Mylin A. Torres, William C. Wood> ;Oncology. 2018 Aug 15
• We have to talk about it: Bringing fertility into the conversation for young women with breast cancer
  Caitlin E. Taylor, Jane L. Meisel> ;Cancer. 2021 Aug 15
• 3 citations
  Weighing the influence of race and obesity on outcomes in patients with early-stage breast cancer
  Caitlin E. Taylor, Jane L. Meisel> ;Cancer. 2021 Mar 15
• 22 citations
  Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
  Jane L. Meisel, Jing Zhao, Aili Suo, Chao Zhang, Zhimin Wei, Caitlin E. Taylor, Ritu Aneja, Uma Krishnamurti, Zaibo Li, Rita Nahta, Ruth O'Regan, Xiaoxian Li> ;Clinical Breast Cancer. 2020 Feb 1
• Join now to see all